The biopharmaceutical landscape in 2026 has entered a period of profound structural realignment, transitioning from the reactive post-pandemic restructuring of previous years into an era defined by aggressive, data-driven consolidation. Following a record-setting 2025, which saw global pharmaceutical and biotechnology deal values exceed $240 Billion, the current year is characterised by an acceleration of strategic urgency. This momentum is underpinned by a confluence of stab

The European healthcare technology and medical technology (MedTech) landscape entering 2026 stands at a profound inflection point, characterised by a transition from the speculative fragmentation of the early 2020s to a disciplined era of "industrial maturity". Following a period of post-pandemic recalibration in 2024 and a tentative recovery in 2025, the market is poised for a robust, albeit structurally transformed, resurgence in capital deployment and mergers and acquisiti